IP Verse

Samsung Bioepis Nl competitive analysis

Explore patent oppositions filed by Samsung Bioepis Nl against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Jun 25, 2026

Patent Number	Title	Applicant	Opposition Date
EP3167888	Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement	ALEXION PHARMACEUTICALS	May 2, 2024
EP3883606	Safe And Effective Method Of Treating Ulcerative Colitis With Anti-Il12/Il23 Antibody	JANSSEN BIOTECH	Feb 5, 2024
EP3403646	Liquid Pharmaceutical Composition	FRESENIUS KABI DEUTSCHLAND	Oct 5, 2022
EP3145488	Liquid Pharmaceutical Composition	ARES TRADING	Apr 22, 2021
EP3212667	Pharmaceutical Anti-Tnf-Alpha Antibody Formulation	RICHTER GEDEON NYRT	Dec 12, 2019

Discover the latest PTAB cases involving Samsung Bioepis Nl, highlighting their recent legal challenges and patent disputes.

IP litigation analysis comparing Samsung Bioepis Nl with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Jun 25, 2026

Company	Oppositions Filed	Oppositions Faced	PTAB Cases Filed	PTAB Cases Faced
SAMSUNG BIOEPIS NL	4	-	-	-
ALEXION PHARMACEUTICALS	3	11	-	8
ARES TRADING	5	16	-	1
FRESENIUS KABI DEUTSCHLAND	129	25	-	-